Non-Small Cell Lung Cancer beyond Biomarkers: The Evolving Landscape of Clinical Trial Design

Author： Dimou Anastasios Papadimitrakopoulou Vassiliki

Publisher： MDPI

E-ISSN： 2075-4426|4|3|386-401

ISSN： 2075-4426

Source： Journal of Personalized Medicine, Vol.4, Iss.3, 2014-06, pp. : 386-401

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Targeted Therapies in Non-Small Cell Lung Cancer—Beyond EGFR and ALK

By Rothschild Sacha I.

Cancers, Vol. 7, Iss. 2, 2015-05 ,pp. : 930-949

MDPI

Access to resources Recommend Favorite

A Phase I Trial of Sunitinib and Rapamycin in Patients with Advanced Non-Small Cell Lung Cancer

Chemotherapy, Vol. 59, Iss. 1, 2013-04 ,pp. : 8-13

Karger

Access to resources Recommend Favorite

Phase II Trial of Biweekly Chemotherapy with Docetaxel and Cisplatin in High-Risk Patients with Unresectable Non-Small Cell Lung Cancer

Chemotherapy, Vol. 59, Iss. 3, 2013-10 ,pp. : 159-166

Karger

Access to resources Recommend Favorite

A Phase I Trial of Temsirolimus and Pemetrexed in Patients with Advanced Non-Small Cell Lung Cancer

Chemotherapy, Vol. 61, Iss. 3, 2016-01 ,pp. : 144-147

Karger

Access to resources Recommend Favorite

Biweekly Vinorelbine and Gemcitabine as Second-Line Treatment and Beyond in Non-Small Cell Lung Cancer

Chemotherapy, Vol. 56, Iss. 5, 2010-10 ,pp. : 353-358

Karger

Access to resources Recommend Favorite